# ASLAN Pharmaceuticals Pte.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aslan-pharmaceuticals-pte

- Industry: Pharmaceuticals
- Headquarters: Singapore, Singapore
- Website: www.aslanpharma.com
- Total disclosed funding: $77M
- Latest round: Series C (Jan 7, 2016)
- Investors on record: 8

## About

Founded in 2010, chaired by Carl Firth as CEO, and based in Singapore, ASLAN Pharmaceuticals Pte. Ltd is a clinical-stage immunology-focused biopharmaceutical company developing treatments and therapies focused on atopic dermatitis, and other immunology indications and autoimmune diseases. The company operates across Taiwan, China, and Australia. The company trades on NASDAQ under the ticker symbol ASLN. 	

ASLAN Pharmaceutical’s portfolio is led by ASLAN004, a monoclonal antibody targeting IL-13Ra1, a treatment for atopic dermatitis and asthma. ASLAN004 is in Phase 1 of the clinical trials. Additionally, the company’s pipeline includes ASLAN003, an oral inhibitor of DHODH in the development of autoimmune diseases such as Dengue and Zika viruses. The company is currently assessing the potential of ASLAN003 as a treatment for Covid-19. As of 2021, the company has an AhR antagonist, a druggable transcription factor that acts as a master regulator of the immune system, in the discovery stage for oncology. 

The company plans to begin the Phase 2b study of ASLAN004 in the second half of 2021 and to roll out its cancer drug in China, the US, and Europe in the future.

## Funding rounds

- Series C, Jan 7, 2016, $9M — MVP Capital Partners
- Series C, Dec 7, 2015, $34M — BioVeda Capital, 5Y Capital, Sagamore Investments, Cenova Ventures, Haitong International Securities Group, Tianda Pharmaceuticals Limited, Accuron Technologies Limited
- Series B, Oct 10, 2013, $22M — BioVeda Capital, 5Y Capital, Sagamore Investments, Cenova Ventures
- Series A, Jul 1, 2011, $12M — BioVeda Capital

## Investors

- BioVeda Capital (https://capitalatlas.ai/funds/bioveda-capital) — Series A, Series B, Series C
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series B, Series C
- Sagamore Investments — Series B, Series C
- Cenova Ventures (https://capitalatlas.ai/funds/cenova-ventures) — Series B, Series C
- Haitong International Securities Group — Series C
- Tianda Pharmaceuticals Limited — Series C
- Accuron Technologies Limited — Series C
- MVP Capital Partners (https://capitalatlas.ai/funds/mvp-capital-partners) — Series C